Association Review
In brief
The association between BTK (Bruton Tyrosine Kinase) and Leukemia, Chronic Lymphocytic is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
8
Compounds
4
Trials
234of 717 via BTK compounds
Publications
0
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Leukemia, Chronic Lymphocytic
The disorder
13 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Phenotype
Clinical features
2 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
06
Interventions
Therapeutics
4 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials
717 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
08
Provenance
References & sources
10 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access